introduction
The emergence of a non-germ-cell tumor alongside germ-cell tumor (GCT) carries a guarded prognosis [1] [2] [3] [4] [5] [6] [7] [8] [9] . Non-GCT elements are reported in 3%-7% of patients undergoing postchemotherapy retroperitoneal lymph node dissection (RPLND) [3, 10] . The most common histologies are sarcomas, mainly rhabdomyosarcoma and primitive neuroectodermal tumor (PNET) [3, 4, 9, 10] .
PNETs are of two main types-peripheral and central. Peripheral PNET represents a spectrum of diseases known as the Ewing's sarcoma (EWS) family of tumors. These tumors express one of the several reciprocal translocations all involving breakpoints that are clustered within a single gene locus on chromosome 22 [11] . Central PNETs are primitive embryonicappearing tumors that most characteristically occur in the central nervous system of children and do not carry the EWS translocations. Most PNETs arising from GCT exhibit morphological features of central PNET [12] .
Despite arising within GCT, PNET and other transformed histologies are usually resistant to additional cisplatin-based treatment [1, 4, 6, 7, 9] . Therefore, chemotherapy targeted at the histology of the transformed element is sometimes used. Responses were mainly observed in patients with adenocarcinoma, leukemia and sarcoma [13, 14] . Chemotherapy regimens for EWS often include vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide, depending upon the stage of disease [15] . Effective treatment of central PNETs also frequently utilizes cyclophosphamide, ifosfamide and etoposide [16] . We have used PNET-specific chemotherapy in selected patients. We report our 20-year experience and describe patient outcome, the response to PNET-specific chemotherapy and the rate of EWS translocation.
patients and methods
We searched the Indiana University testis cancer database and pathology files from January 1988 to December 2007 to identify all patients with PNET involving the testis or associated with GCT. The Indiana University Institutional Review Board approved the study. All pathology was reviewed at Indiana University. PNET was detected according to previously reported criteria [12] . Transformed histology was limited to PNET in 75 patients, while 6 had other coexisting non-germ-cell components.
We acquired follow-up data from September to December 2008 from our institution, referring facility records, and by direct patient or first-degree original article family contact. Six (7%) patients were lost to follow-up, defined as having a last contact date of >12 months before analysis. The Social Security Death Index was used to corroborate survival status. None of these six were reported dead at the time of analysis, and all were disease free at last follow-up. Primary RPLND was our preferred approach to clinical stage I or surgically suitable stage II testicular PNET and normal postorchiectomy serum tumor markers. All other patients received initial chemotherapy, usually cisplatin based for GCT. Complete response to chemotherapy was defined as normalization of serum tumor markers and no residual mass >1 cm. We followed these patients without additional treatment. Patients with a resectable residual mass, ‡1 cm, were offered surgery. We categorized patients according to the most aggressive component within the surgical specimen (PNET > nonteratomatous GCT > teratoma).
PNET relapse was defined as disease progression in the absence of marker elevation occurring in a previously stable anatomic site known to harbor PNET or when biopsy confirmation of PNET was available. Patients who relapsed with PNET underwent further surgery when judged resectable. When surgery was not feasible, chemotherapy was applied. Different regimens were used during the study period. After 2000, PNET-specific chemotherapy was administered consisting of cyclophosphamide 1200 mg/m given every 3 weeks for six courses or until progression or undue toxicity. A patient was considered assessable for response when at least 1 day of chemotherapy was given. All deaths were cancer related, including two patients who died after surgery while being disease free. The Kaplan-Meier method was used to analyze survival time. Differences in survival probabilities were assessed using the log-rank test with significance at P value < 0.05. Statistical analysis was carried out with SPSS software version 16.0 (SPSS Inc., Chicago, IL).
Genetic studies were carried out on paraffin-embedded tissue blocks containing PNETs from 14 patients. Patients were selected on the basis of tissue availability. EWS translocation was detected by FISH. We used a commercial break-apart probe set flanking the EWS breakpoint region 1 gene on chromosome 22q12 (Vysis Inc., Downers Grove, IL). We used a cut-off value of 20% for the proportion of tumor cells having a chromosome 22 translocation.
results
Our cohort included 81 consecutive patients. During the study period, 3022 patients underwent RPLND at Indiana University, 73 (2.4%) of whom had PNET in the primary tumor or metastatic sites. In 80 patients, PNET was associated with GCT elements, 75 of whom harbored teratoma in the primary tumor or metastasis. One patient had pure PNET detected in the testis and retroperitoneum.
Seventy-six patients contained PNET in the primary tumor or in the surgical specimen following initial chemotherapy. Baseline characteristics of these 76 patients are outlined in Table 1 , and their outcome is reported in the next two sections. The remaining five patients did not harbor PNET at initial presentation. These five relapsed with PNET following primary chemotherapy and resection of residual teratoma.
Six patients who presented with clinical stage I underwent surveillance outside our institution despite harboring PNET in the testis. They were referred to us following relapse, and three are dead of disease (DOD). Three of these six patients relapsed with localized retroperitoneal PNET and underwent RPLND. Three patients relapsed with more advanced disease and were treated with chemotherapy. The outcome of these six patients is reported in the following sections according to the treatment administered initially, after surveillance, and at relapse.
primary RPLND
Twenty-six patients with clinical stage I (n = 18) or II (n = 8) underwent primary RPLND. Median follow-up was 48 months (range 2-207). PNET was present in the orchiectomy specimen in 17 of 18 with clinical stage I disease. Of these 17, retroperitoneal PNET was detected in 4 (24%) and GCT in 4 (24%). The remaining nine (53%) were pathologically negative. An additional patient with clinical stage I without a PNET in the testis had an incidental finding of retroperitoneal PNET. All eight who presented with clinical stage II disease harbored PNET in the retroperitoneum. Six of these eight also had PNET in the testicle.
Overall, 13 patients exhibited PNET in the retroperitoneum and 13 did not. All 13 patients who harbored PNET in the testicle but not in the retroperitoneum are alive and free of PNET relapse. Nine of 13 patients who had PNET in the RPLND specimen have currently NED, and 4 are DOD. Four patients relapsed after RPLND with PNET, three in the retroperitoneum and one in cervical nodes. Three of these four are DOD and one has NED following redo-RPLND. Additional patient died of GCT relapse. The three who relapsed in the retroperitoneum after surgery underwent RPLND outside Indiana University and were referred to us at the time of relapse.
initial chemotherapy
This group consisted of 50 patients with disseminated disease, who harbored PNET in the primary tumor and/or initial metastatic sites (Figure 1 ). Median follow-up was 38 months (range 4-235). Postorchiectomy serum tumor markers were elevated in 38 patients. Nineteen of the 33 patients who had PNET in the primary tumor contained PNET in metastatic sites.
Five patients with PNET in the primary tumor achieved a complete response to initial GCT chemotherapy. All five relapsed with PNET, including four in the retroperitoneum. Forty-five obtained a partial response to chemotherapy (GCT chemotherapy in 44 and PNET-specific chemotherapy in 1). Two patients had inoperable liver or bone PNET after initial chemotherapy, and both are DOD. A complete resection of residual tumor was achieved in the remaining 43. All 12 patients who had only residual teratoma have currently NED, whereas 10 of 27 (37%) who harbored PNET in the surgical specimen are alive. The 2-and 5-year cancer-specific survival for patients who underwent complete resection of PNET following initial chemotherapy was 66% (95% CI 49% to 87%) and 40% (95% CI 25% to 66%), respectively. In a univariate analysis, the only adverse predictor of survival was the need to resect adjacent organs during postchemotherapy surgery (Table 2) .
PNET relapse
Thirty-one patients relapsed with PNET after obtaining NED status to initial chemotherapy or primary RPLND (Table 3) . Late PNET relapse, 3-10 years after initial treatment, occurred in three patients. The most common PNET relapse site was the retroperitoneum, involving 20 patients, 16 of whom had In parenthesis is the number of patients who had PNET detected in the primary tumor. original article Annals of Oncology a previous RPLND. The estimated 2-year cancer-specific survival measured from the time of relapse was 38% (95% CI 24% to 60%). Eleven patients underwent surgery as initial treatment of the relapse. Two of these 11 have currently NED, 2 are alive with disease (AWD) and 7 are DOD. The remaining 20 relapsed with disease not suitable for surgery and received chemotherapy, radiation or supportive care only. One of these 20 has currently NED following PNET-specific chemotherapy and subsequent surgery, 2 are AWD and 17 are DOD. Non-PNET-specific chemotherapy or radiation therapy was administered in 11 patients without durable responses.
PNET-specific chemotherapy
CAV/IE was administered in 12 patients. Two patients received CAV/IE adjuvant to surgery, and both have continuous NED. Ten patients were treated due to extensive PNET not suitable for surgery. Eight of these 10 had at least one prior platinum-based combination chemotherapy regimen. Of these 10 patients one is currently NED at 33 months, and 4 are AWD at 21 to 73 months from initiation of CAV/IE. Five patients are DOD. All patients who are currently alive underwent surgery following CAV/IE. Eight achieved an objective response to CAV/IE, and six had subsequent surgery. Of these six patients, two had only teratoma remaining in the post-CAV/IE surgical specimen, and four had residual PNET.
EWS translocation
Specimens from 14 patients were investigated for the presence of the EWS translocation. Only one case was positive showing 22% of tumor nuclei with a positive signal.
discussion
The finding of isochromosome 12p, a marker of GCT, in most transformed elements arising within GCT, including PNET, supports an origin from a GCT element [5, 13, 17] . Teratoma is the most likely source of the transformed histologies. Several findings support this hypothesis. Teratoma is a pluripotential tissue that can potentially undergo malignant transformation along ectodermal, endodermal, or mesodermal elements, thus explaining the diversity of histologies encountered. Teratoma originating in the adult testis is capable of metastasis [18] , and chromosomal imbalances are frequently found in primary testicular teratoma [19] or residual teratoma following chemotherapy [20] . Finally, teratoma often accompanies transformed histologies as seen in our study [3, 4, 8, 14] .
Three observations on the pathogenesis of PNET are apparent from this study. (i) The transformation to PNET is an early event since 76 of 81 patients (94%) contained PNET at initial presentation.
(ii) The spread of testicular PNET resembles that of GCT, i.e. initially to the retroperitoneum. Seventeen clinical stage I patients with testicular PNET underwent primary RPLND and four had PNET in the retroperitoneum. The remaining 13 who did not harbor retroperitoneal PNET are free of PNET relapse. Furthermore, although relapses were frequently seen in patients with retroperitoneal PNET, they were mainly local recurrences. (iii) PNET of GCT origin does not usually carry the EWS translocation. This finding, in conjunction with the morphology [12] , supports a relationship to central nervous system PNET.
We ordinarily endorse the concept of surveillance for clinical stage I GCT. That is done with the philosophy that if a patient develops recurrent metastatic GCT, the patient can be cured with chemotherapy. However, the presence of PNET in the primary tumor makes it more likely that a recurrence will also contain a PNET element. Sixty-four percent of patients, who presented with metastatic disease and PNET in the primary, were found to contain PNET in metastasis. Since cisplatin chemotherapy is ineffective and PNET-specific chemotherapy has only limited curative role, we encourage patients with stage I disease to undergo primary RPLND if there is PNET in the testis. Of the 13 patients who underwent primary RPLND and were found to contain retroperitoneal PNET, 9 remained free of PNET relapse.
Patients who present with advanced disease not suitable for surgery should receive primary chemotherapy. The chemotherapy is usually directed at the GCT component. Our policy is to follow patient without surgery after obtaining complete remission [21] . The presence of PNET in the primary tumor may be one exception where RPLND should be carried out. Five patients were followed without RPLND after obtaining a complete remission. All relapsed with PNET, including four in the retroperitoneum.
The finding of residual PNET after cisplatin-based chemotherapy is associated with increased risk of relapses and references
